中年稳压胶囊对SHR大鼠血压干预实验观察
2021-07-20陈春花许滔
陈春花 许滔


【摘 要】 目的:课题通过实验评估中年稳压胶囊对自发性高血压大鼠(SHR)的降压作用,总结中医治肝法降压理论机制,探索治肝降压法治疗原发性高血压的机制。方法:实验选用56只10周龄SHR大鼠,随机分为空白组、实验组(中年稳压胶囊组),并设同龄SD大鼠(7只)为正常对照组,每周测尾动脉无创血压2次,分别对实验组给药后各组大鼠第1、3、5、8周血压进行统计分析。结果:正常SD大鼠不同時期SBP无统计学差异(P>0.05),同期SD大鼠与各SHR大鼠组血压SBP存在显著差异(P<0.05)。SHR空白组及实验组初始血压SBP无统计学意义(P>0.05)。给药后同期各SHR大鼠血压结果对比:第1周空白组及实验组SBP无统计学意义(P>0.05),各组与初始血压相比较,无显著差异;给药后第3周开始空白组各组SBP与初始血压相比较,有显著差异(P<0.05),空白组及实验组SBP有显著差异(P<0.05)。给药后第5周血压对比分析:空白组及实验组SBP有显著差异(P<0.05),期间最高血压SBP达到202 mmHg;各组大鼠在给药后第8周血压值统计:空白组及实验组SBP有显著差异(P<0.05),空白组各组血压与初始血压相比较,有显著差异(P<0.05),各高血压大鼠组与正常对照组SBP存在显著差异(P<0.05)。结论:中年稳压胶囊对SHR大鼠血压有较明显的降压作用,中年高血压患者发病与肝密切相关,认为中医治肝降压法对中年高血压有较好的疗效。
【关键词】 原发性高血压;中医治肝降压法;中年稳压胶囊;SHR大鼠
【中图分类号】R285.1 【文献标志码】 A 【文章编号】1007-8517(2021)09-0029-06
Abstract:Objective This project through experimental assessment of the middle-aged regulator capsule.Take this summary to heal Liver method step-down theory mechanism,such as calming the liver and suppressing hyperactivity of Yang,clearing away liver-fire,soothing the liver and regulating and circulation of Qi,nourishing the liver.experiment research to cure the step-down theory of the Liver,the antihypertensive effect in SHR (Spontaneously Hypertensive Rats) and And reveals the liver step-down method.And reveals clinical effective prescription inside the capsule middle-aged hypertension intervention acting targets,to further explore cure liver step-down method of treatment of primary hypertension mechanism.Methods The experiment selected 56 SHR rat were randomly divided into blank control group and experimental groups (each of the large group of middle-aged regulator capsule group),and selected 7 SD rat were normal control.In 1,3,5,8 weeks,every week manometry 2times after drenching sacrificed rats.Access to the corresponding data were statistically analyzed and compared.Results There was no significant difference in SBP among different periods of SD rats (P>0.05),there were significant differences in SBP between SD rats and SHR rats in the same period ( P<0.05).The SBP of SHR blank group and experimental group had no significant difference (P>0.05).There were no significant differences in SBP between the Control Group and the experimental group at the 1st Week (P>0.05),SBP between the control group and the experimental group at the 3rd week (P<0.05),SBP between the control group and the experimental group at the 3rd week (P<0.05),SBP between the control group and the experimental group at the 5th week (P<0.05),SBP between the control group and the experimental group at the 5th week (P<0.05).There was significant difference in SBP between the blank group and the experimental group at the 8th week after administration (P<0.05).It is suggested that the middle-aged regulator capsule has significant antihypertensive effect on hypertension in rats.There were significant differences in SBP between the blank group and the experimental group (P<0.05),between the blank group and the experimental group (P<0.05),and between the hypertensive group and the control group (P<0.05).Conclusion Traditional Chinese medicine think that the incidence of middle-aged patients with hypertension with the liver are closely related.The middle-aged regulator capsule of that middle-aged regulator mechanism of the capsule by adjusting liver to achieve the treatment of high the purpose of the blood pressure.
Keywords:Primary Hypertension;The Method of Traditional Chinese Medicine Treat liver for Lowering Blood Pressure;The Capsule of Stabilizing Mid Adult's Blood Pressure; SHR Rat
高血壓是临床的常见病、多发病,2002年统计中国高血压患者为1.6亿。随着人民生活质量的不断提高,高血压患者年龄呈现越来越低龄化的趋势,2005年有关我国高血压流行病学研究结果显示中年(45~59岁)高血压患者的患病率达到29.7%[1],较1991年全国高血压普查结果[2]升高了9.00%。在我国40岁以上人群的死亡原因中,心血管病和脑血管病分别列为第1位和第3位,而总死亡的第一危险因素是高血压[3]。这个年龄区间中患高血压的大多数人还在工作的第一线,由于对西药副作用的畏惧,特别是降压药物对男性性功能的影响,服药依从性差,血压控制达标率低。流行病学调查显示,高血压致残、致死的并发症严重危害了人类健康,对千万个家庭造成损害,耗费国家大量的卫生资源,因此对高血压的有效防治仍然是亟待解决的医学问题和社会问题。其中,中……
